Journal
CELL STEM CELL
Volume 12, Issue 4, Pages 487-496Publisher
CELL PRESS
DOI: 10.1016/j.stem.2013.01.009
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science (JSPS)
- Alzheimer's Association [IIRG-09-132098]
- JST Yamanaka iPS Cell Special Project
- CREST
- Ministry of Health, Labour and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan [22110007]
- Japan Research Foundation for Clinical Pharmacology
- Grants-in-Aid for Scientific Research [23123510, 24590040, 22110007, 21248015, 24700367, 23592093, 23249049, 24500408, 22129006, 24790260, 24790276] Funding Source: KAKEN
Ask authors/readers for more resources
Oligomeric forms of amyloid-beta peptide (A beta) are thought to play a pivotal role in the pathogenesis of Alzheimer's disease (AD), but the mechanism involved is still unclear. Here, we generated induced pluripotent stem cells (iPSCs) from familial and sporadic AD patients and differentiated them into neural cells. A beta oligomers accumulated in iPSC-derived neurons and astrocytes in cells from patients with a familial amyloid precursor protein (APP)-E693 Delta mutation and sporadic AD, leading to endoplasmic reticulum (ER) and oxidative stress. The accumulated A beta oligomers were not proteolytically resistant, and docosahexaenoic acid (DHA) treatment alleviated the stress responses in the AD neural cells. Differential manifestation of ER stress and DHA responsiveness may help explain variable clinical results obtained with the use of DHA treatment and suggests that DHA may in fact be effective for a subset of patients. It also illustrates how patient-specific iPSCs can be useful for analyzing AD pathogenesis and evaluating drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available